Advanced Filters
noise

ovarian-cancer Clinical Trials

A listing of ovarian-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 561 clinical trials
H Hao Wen, MD

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer

This prospective observational study is to assess the dynamics of circulating tumor DNA (ctDNA) in patients with advanced epithelial ovarian cancer (EOC) undergoing surgery, adjuvant chemotherapy, followed by poly adenosine diphosphate-ribose polymerase (PARP) inhibitors until disease progression or the end of the study. All patients will be closely monitored throughout …

18 - 70 years of age Female Phase N/A
H Hongyu Xie, PhD

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels …

18 - 75 years of age Female Phase N/A
A Anniina Färkkilä, MD PhD

Systems Oncology Approach to Optimize Ovarian Cancer Treatment

The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, …

years of age Female Phase N/A
Q Qinglei Gao, MD. PhD

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. …

18 years of age Female Phase N/A
A Amy Overby

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

18 years of age Female Phase N/A
M Medical Ethics Committee of Xiangya Hospital

Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression

The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are: What is the difference in urinary protein composition between patients with ovarian cancer and those without it? Can these differences in urinary …

18 years of age Female Phase N/A
C Christine Pappaterra

Clinical Pre-screening Protocol for Ovarian Cancer

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. …

18 years of age Female Phase N/A
S Sandro Pignata, MD, PhD

PRO for Fighting FT in Ovarian Cancer

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

years of age Female Phase N/A
V Vincenzo Canzonieri, MD, PhD

Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).

The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue …

18 years of age Female Phase N/A
H Hao Wen, MD.&PHD

Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )

This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from newly diagnosed ovarian cancer.

40 - 75 years of age Female Phase N/A

Simplify language using AI